A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

PURPOSE: In preclinical studies the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patients with relapsed, refr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Gojo, Ivana, Beumer, Jan H., Pratz, Keith W., McDevitt, Michael A., Baer, Maria R., Blackford, Amanda L., Smith, B. Douglas, Gore, Steven D., Carraway, Hetty E., Showel, Margaret M., Levis, Mark J., Dezern, Amy E., Gladstone, Douglas E., Ji, Jiuping, Wang, Lihua, Kinders, Robert J., Pouquet, Marie, Ali-Walbi, Ismail, Rudek, Michelle A., Poh, Weijie, Herman, James, Karnitz, Larry M., Kaufmann, Scott H., Chen, Alice, Karp, Judith E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290001/
https://ncbi.nlm.nih.gov/pubmed/27503200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0984
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados